Physician profile
Raymond E Tsao
NPI 1497933998
$4,426.73
in general payments reported to CMS, 2019-2025
49 companies · $72.77 in 2025
The $72.77 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,013 · 2020: $547 · 2021: $93.85 · 2022: $244 · 2023: $358 · 2024: $99.00 · 2025: $72.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.77 |
| Education | $150.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.57 | 2019-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $367.75 | 2019-2022 | |
| Pfizer INC. | $330.68 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $240.97 | 2019-2022 | |
| Genentech USA, INC. | $225.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $212.55 | 2019-2023 | Lynparza, Keytruda |
| Seagen INC. | $209.34 | 2019-2023 | Tukysa |
| Daiichi Sankyo INC. | $182.46 | 2019-2023 | Enhertu |
| Celgene Corporation | $175.21 | 2019-2023 | Recothrom |
| Lilly USA, LLC | $167.97 | 2019-2023 | Verzenio, Jaypirca |
| Amgen INC. | $153.55 | 2019 | |
| Genzyme Corporation | $130.98 | 2019-2023 | |
| Abbvie INC. | $129.84 | 2019-2020 | |
| Janssen Biotech, INC. | $122.45 | 2019-2024 | Darzalex |
| Puma Biotechnology, INC. | $109.08 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Tsao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.